Intensity Therapeutics, based in Westport, reports that its
INT230-6 induces significant cancer cell death in the tumor microenvironment. Thereafter, eradication of the tumor by INT230-6 requires T lymphocytes and leads to a potent and durable systemic anti-cancer T-cell-dependent immunity against the tumor.

Chief Executive Officer Lewis H. Bender said, “We plan to initiate clinical studies of INT230-6 as soon as possible. If our preclinical results translate in cancer patients, INT230-6 could represent a significant advance in the treatment of many types of solid tumor cancers, potentially providing oncologists with a less toxic means to destroy visible tumors, eliminate metastases and prevent disease recurrence.”